FindTrial
Sign In

Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age

Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04957927
Enrollment
60
Registered
2021-07-12
Start date
2020-12-12
Completion date
2021-12-12
Last updated
2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinitis

Keywords

Allergic Rhinitis in children, Montelukast, Intranasal Fluticasone Propionate

Brief summary

To determine the Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age.

Detailed description

Our study will compare the Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age as in our population compliance with oral medication is better among patients, and is socially and culturally more acceptable.

Interventions

DRUGEffectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age

Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age

Sponsors

King Edward Medical University
CollaboratorOTHER
Usama Azhar
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Intervention model description

Randomized control trial

Eligibility

Sex/Gender
ALL
Age
2 Years to 5 Years
Healthy volunteers
No

Inclusion criteria

* Age:02 to 05 Years of Age * both genders will be included. * patients diagnosed with allergic rhinitis.

Exclusion criteria

* patients older than 05 years of age * a positive history of HIV,TB,Immune deficiency. * any nasal structural abnormality i.e.polyps,deviated nasal septum. * history of frequent nasal bleeding,epistaxis. * concomitant asthma.

Design outcomes

Primary

MeasureTime frameDescription
Improvement in Day and Night time nasal symptoms score of Allergic Rhinitis2 monthsEffectiveness will be assessed by noticing the Improvement in Day and Night time nasal symptoms score of Allergic Rhinitis.

Countries

Pakistan

Contacts

Primary ContactUsama Azhar, MBBS
dr.usama.azhar@gmail.com0923336506169
Backup ContactMuhammad Haroon Hamid, MBBS,FCPS
profharoon@kemu.edu.pk0923008880916

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026